With funding from RWJFs Health Games Research national program.

$1.85 million grant to study how digital games can improve players’ health behaviors and outcomes Researchers seek to discover how interactive video gaming can be made to improve physical activity, prevention behaviors and self-administration of chronic circumstances The Robert Timber Johnson Basis today announced more than $1 Click to read more about the treatment .85 million in grants for research that may offer unprecedented insight into how digital games can improve players’ health behaviors and outcomes. With funding from RWJF’s Health Games Research national program, nine research teams in the united states will conduct extensive studies to discover, for example, the way the popular dance pad gaming Dance Dance Revolution will help Parkinson’s patients decrease the risk of falling, how Wii Active might be most implemented in high schools to greatly help overweight students get rid of weight effectively, how a cellular phone video game with a breath interface might help smokers stop or reduce their tobacco use, or how facial recognition video games might be designed to help people with autism figure out how to identify others’ feelings.

Caserta, M.D., Sandra Fowler, M.D., Jorge Lujan-Zilbermann, M.D., Gregory A. Storch, M.D., Roberta L. DeBiasi, M.D., Jin-Little Han, M.D., Ph.D., April Palmer, M.D., Leonard B. Weiner, M.D., Joseph A. Bocchini, M.D., Penelope H. Dennehy, M.D., Adam Finn, M.D., Paul D. Griffiths, M.D., Suzanne Fortune, M.B., Ch.B., Kathleen Gutierrez, M.D., Natasha Halasa, M.D., James Homans, M.D., M.P.H., Andi L. Shane, M.D., M.P.H., Michael Sharland, M.D., Kari Simonsen, M.D., John A. Vanchiere, M.D., Ph.D., Charles R. Woods, M.D., Diane L. Sabo, Ph.D., Inmaculada Aban, Ph.D., Huichien Kuo, M.S., Scott H. James, M.D., Mark N. Prichard, Ph.D., Griffin Jill, R.N., Dusty Giles, R.N., Edward P. Acosta, Pharm.D., and Richard J. Whitley, M.D. For the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Research Group: Valganciclovir for Symptomatic Congenital Cytomegalovirus Disease Congenital cytomegalovirus infection may be the leading nongenetic reason behind sensorineural hearing loss1-4 and is the most frequent known viral cause of mental retardation5; the infections affects 0.6 to 0.7 percent of live births in industrialized countries.6-8 A complete of 10 percent of congenitally infected neonates have symptomatic disease at birth, of whom 35 percent have sensorineural hearing reduction, up to two thirds have neurologic deficits, and 4 percent die through the newborn period.7-11 Although congenital CMV contamination is rare overall, it accounts for 21 percent of children with hearing loss in birth and 24 percent of these with hearing loss at 4 years of age.1,12 The National Institute of Allergy and Infectious Illnesses Collaborative Antiviral Study Group discovered that among neonates with symptomatic congenital CMV disease relating to the central nervous system , ganciclovir administered intravenously over an interval of 6 weeks was connected with improved audiologic outcomes at 6 months of life, but there is suggestion that benefit could wane over the first 24 months of life.13 Treated infants acquired fewer developmental delays, according to Denver Developmental evaluations, than untreated infants.14 In a follow-up research, the CASG determined the dose of oral valganciclovir that outcomes in systemic contact with ganciclovir that’s similar compared to that with intravenous ganciclovir.15 Therapy with intravenous ganciclovir or oral valganciclovir for 6 weeks is now an accepted treatment option for patients with symptomatic congenital CMV disease relating to the CNS.16 Methods Research Population and Design Neonates with symptomatic congenital CMV disease, with or without CNS involvement, were qualified to receive enrollment.